Clin Res Cardiol (2022). https://doi.org/10.1007/s00392-022-02002-5

Gender differences with the use of percutaneous left ventricular assist device in cardiogenic shock patients - Results from the Dresden Impella Registry
J. Mierke1, T. Löhn2, T. Nowack1, F. Pöge1, M. C. Schuster1, F. Woitek1, S. Haussig1, K. Ibrahim3, N. Mangner1, C. Pflücke4, A. Linke1
1Klinik für Innere Medizin, Kardiologie und Intensivmedizin, Herzzentrum Dresden GmbH an der TU Dresden, Dresden; 2Zentrum für Innere Medizin, Kreiskrankenhaus Freiberg gGmbH, Freiberg; 3Klinik für Innere Medizin I, Klinikum Chemnitz gGmbH, Chemnitz; 4Klinik für Innere Medizin I, Städtisches Klinikum Görlitz, Görlitz;

Background: Cardiogenic shock (CS) is a state of end-organ hypoperfusion due to cardiac output failure and is characterized by high mortality. Percutaneous left ventricular assist devices (pLVAD), like the Impella® system, support the left ventricular function and provide a sufficient oxygen supply to all tissues, which might improve outcome. In the current study, we investigated gender-specific differences in a large, propensity score matched cohort of patients receiving an Impella CP® in CS. Beside all-cause mortality, we focused on requirement of hemodialysis and surrogate parameters like development of systemic inflammatory response syndrome (SIRS), or sepsis.

Methods: The Dresden Impella Registry is an ongoing registry including more than 650 patients since 2014. Among, a total of 95 female and 237 male patients received an Impella CP® in CS. Two groups of similar sample size (n=60) resulted after propensity score matching. A logistic regression model was used for adjustment of the baseline characteristics (nearest neighbor matching). Kaplan-Meier curves at 30, 180 and 365 days as well as clinical, laboratory and hemodynamic parameters were compared between male and female patients.

Results: The propensity score matched cohorts showed a well balancing without significant differences between baseline characteristics. At time of admission, female patients were 68.9 ±1.8 years old, male patients 67.2 ±1.5 years. A cardiopulmonary resuscitation (CPR) before pLVAD was performed in 53.3% in both groups. The comparison of mean arterial pressure, norepinephrine and dobutamine dosage showed no differences initially and in course. The left ventricular ejection fraction did not differ between both cohorts (♀ 28.6±2.3% vs. ♂ 26.7±1.7%, p=0.885). The duration of left ventricular unloading was 44.1±6.5 h among female patients and 56.0±7.3 h among male patients (p=0.119).

The all-cause mortality showed no difference at 30, 180, and 365 d (30 d: ♀ 61.7±6.3% vs. ♂ 56.7±6.4%, p=0.349; 180 d: ♀ 73.3±5.7% vs. ♂ 68.3±6.0%, p=0.312; 365 d: ♀ 76.7±5.5% vs. ♂ 70.0±5.9%, p=0.312).

However, hemodialysis was less frequently required in female patients (♀ 28.3% vs. ♂ 45.8%, p=0.049). The duration of hemodialysis did not differ between the groups (♀ 123.9±57.8 h vs. ♂ 108.1±56.3 h, p=0.744). Furthermore, occurrence of SIRS and sepsis were less frequently observed in female patients (SIRS ♀ 45.0% vs. ♂ 75.0%, p=0.042; sepsis ♀ 43.3% vs. ♂ 62.7%, p=0.034).

Conclusion: All-cause mortality showed no gender-specific differences in a well-balanced propensity score matched analysis of CS patients receiving LV-unloading with a pLVAD. However, females had a decreased requirement of hemodialysis and a less frequent occurrence of SIRS and sepsis. Further studies are needed to investigate whether these differences might improve outcome in larger cohorts.


mean±SEM

Female (n=60)

Male (n=60)

p

Age a

68.9±1.8

67.2±1.5

0.152

BMI kg/m²

27.9±0.7

27.4±0.7

0.254

Diabetes mellitus type II %

35.0

38.3

0.705

Renal failure %

36.7

28.3

0.330

Hypertension %

75.0

75.0

1.000

PAD %

10.0

11.7

0.769

CAD %

61.7

55.0

0.459

History of AMI %

15.0

13.3

0.793

No %

46.7

46.7

1.000

In-hospital %

35.0

31.7

0.699

Out-of-hospital %

18.3

21.7

0.648

Duration CPR min (mean±SEM)

34.7±7.9

22.0±3.1

0.650

Myocardial infarction %

58.3

71.7

0.126

Decompensated cardiomyopathy %

16.7

18.3

0.810

Serum lactate (0h) mmol/l

7.93±0.67

7.48±0.71

0.515

NE dosage (0h) µg/kg/min

0.69±0.14

0.53±0.07

0.734

 


https://dgk.org/kongress_programme/jt2022/aV56.html